NCT06836284Recruiting
The Evira Study: Additional Support During Obesity Treatment
Evaluation of a Digital Treatment Tool in Combination With Obesity Medications
Source: ClinicalTrials.gov · Last updated 10 Sept 2026
Brief summary (registry, in English)
The goal of this clinical trial is to evaluate the effect of adding a digi-physical treatment tool as a complement to the local treatment with obesity medication in adolescents with obesity. The main question it aims to answer is: \- Can a combination of a digi-physical treatment tool and obesity medication improve treatment outcomes for patients with obesity compared to patients treated with obesity medications alone? This is a randomized controlled two-arm multicenter study where participants will be randomized to the intervention group (digi-physical treatment+medication) or control group (medication only). Participants will be followed for six months.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- First submitted
- 29 Jan 2025
- Start date
- 13 Feb 2026
- Primary completion date
- 1 Apr 2027
- Lead sponsor
- Karolinska Institutet
- Diseases
- Obesity
- NCT number
- NCT06836284
What you commit to
- Study type: Interventional
- Planned participants: 40
- From 13 Feb 2026 to the primary completion date, 1 Apr 2027
- 3 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Eating disorder requiring treatment within the last six months before inclusion or observed during screening prior to inclusion.
Other illness
- Endocrine disorders other than well-controlled hypothyroidism.
- Severe neuropsychiatric disorders that may affect adherence to the study.
- Somatic conditions that may complicate the evaluation of treatment outcomes, such as patients on irregular oral corticosteroid treatment.
- Hypothalamic or monogenic obesity, and genetic syndromes such as Down syndrome.
Other
- Patients deemed unsuitable for participation by the responsible physician.
Who the study is looking for
- Patients offered liraglutide or semaglutide in accordance with the clinic's routines.
- Aged 12-17 years at the time of inclusion.
- The family agrees to participate in a clinical study.
Age in the registry: 12 years to 17 years · Sex: All · Does not accept healthy volunteers
Sites (3)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| HKH Crown Princess Victoria's Childrens and youth Hospital Linköping Coordinator of this site? Confirm its status | Linköping | Sweden | Recruiting |
| Länsverksamhet Barn- och ungdomsmedicin Sollefteå Coordinator of this site? Confirm its status | Sollefteå | Sweden | Recruiting |
| Ystad lasarett, Barn och ungdomsmedicinmottagningen Coordinator of this site? Confirm its status | Ystad | Sweden | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.